Genmab Interest Income vs Ebitda Analysis

GMAB Stock

USD 21.16 0.51 2.47%

Genmab AS financial indicator trend analysis is much more than just examining Genmab AS latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genmab AS is a good investment. Please check the relationship between Genmab AS Interest Income and its Ebitda accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

Interest Income vs Ebitda

Interest Income vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genmab AS Interest Income account and Ebitda. At this time, the significance of the direction appears to have strong relationship.

The correlation between Genmab AS's Interest Income and Ebitda is 0.71. Overlapping area represents the amount of variation of Interest Income that can explain the historical movement of Ebitda in the same time period over historical financial statements of Genmab AS, assuming nothing else is changed. The correlation between historical values of Genmab AS's Interest Income and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Income of Genmab AS are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Interest Income i.e., Genmab AS's Interest Income and Ebitda go up and down completely randomly.

Correlation Coefficient

0.71

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Ebitda

Most indicators from Genmab AS's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genmab AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.At present, Genmab AS's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 85 B, whereas Tax Provision is forecasted to decline to about 690.5 M.

	2021	2022	2023	2024 (projected)
Interest Expense	13M	21M	27M	16.6M
Depreciation And Amortization	250M	290M	240M	252M

Interest Expense Depreciation And Amortization

Genmab AS fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments
Total Assets		0.98	0.99	0.89	1.0	0.99	-0.39	-0.98	0.99	0.89	0.98	0.95	0.77	1.0	0.54	-0.35	0.95	0.03	0.72	0.93	0.97	1.0	0.9	0.29	0.57	0.99
Short Long Term Debt Total	0.98		0.99	0.93	0.97	1.0	-0.25	-0.99	0.98	0.93	0.99	0.88	0.84	0.98	0.44	-0.43	0.97	-0.03	0.61	0.96	0.99	0.98	0.93	0.12	0.48	0.95
Other Current Liab	0.99	0.99		0.91	0.98	0.99	-0.37	-0.98	0.98	0.94	0.98	0.91	0.84	0.99	0.49	-0.46	0.95	0.06	0.65	0.94	0.98	0.99	0.88	0.25	0.52	0.97
Total Current Liabilities	0.89	0.93	0.91		0.87	0.92	-0.01	-0.92	0.87	0.88	0.92	0.76	0.83	0.9	0.41	-0.44	0.94	-0.07	0.53	0.99	0.93	0.89	0.82	-0.04	0.45	0.84
Total Stockholder Equity	1.0	0.97	0.98	0.87		0.98	-0.42	-0.98	0.99	0.88	0.98	0.95	0.76	1.0	0.55	-0.35	0.94	0.04	0.73	0.91	0.97	1.0	0.9	0.32	0.58	0.99
Property Plant And Equipment Net	0.99	1.0	0.99	0.92	0.98		-0.29	-0.99	0.99	0.92	0.99	0.9	0.83	0.99	0.45	-0.41	0.97	-0.04	0.63	0.96	1.0	0.99	0.9	0.16	0.48	0.96
Current Deferred Revenue	-0.39	-0.25	-0.37	-0.01	-0.42	-0.29		0.28	-0.38	-0.25	-0.27	-0.5	-0.12	-0.36	-0.33	0.23	-0.14	-0.52	-0.46	-0.06	-0.25	-0.38	-0.23	-0.89	-0.33	-0.47
Net Debt	-0.98	-0.99	-0.98	-0.92	-0.98	-0.99	0.28		-0.98	-0.9	-1.0	-0.91	-0.82	-0.99	-0.49	0.4	-0.97	0.04	-0.66	-0.95	-0.98	-0.99	-0.9	-0.16	-0.52	-0.96
Retained Earnings	0.99	0.98	0.98	0.87	0.99	0.99	-0.38	-0.98		0.9	0.98	0.92	0.8	0.98	0.43	-0.4	0.95	-0.02	0.63	0.91	0.98	0.99	0.89	0.23	0.46	0.97
Accounts Payable	0.89	0.93	0.94	0.88	0.88	0.92	-0.25	-0.9	0.9		0.91	0.71	0.89	0.89	0.34	-0.62	0.85	0.09	0.47	0.88	0.93	0.9	0.83	0.05	0.38	0.85
Cash	0.98	0.99	0.98	0.92	0.98	0.99	-0.27	-1.0	0.98	0.91		0.9	0.85	0.99	0.47	-0.42	0.97	-0.04	0.63	0.96	0.99	0.99	0.9	0.16	0.5	0.95
Non Current Assets Total	0.95	0.88	0.91	0.76	0.95	0.9	-0.5	-0.91	0.92	0.71	0.9		0.61	0.94	0.58	-0.21	0.88	0.06	0.78	0.82	0.86	0.94	0.81	0.48	0.6	0.96
Non Currrent Assets Other	0.77	0.84	0.84	0.83	0.76	0.83	-0.12	-0.82	0.8	0.89	0.85	0.61		0.79	0.21	-0.66	0.77	-0.11	0.24	0.82	0.85	0.78	0.74	-0.04	0.25	0.72
Cash And Short Term Investments	1.0	0.98	0.99	0.9	1.0	0.99	-0.36	-0.99	0.98	0.89	0.99	0.94	0.79		0.55	-0.36	0.96	0.01	0.71	0.93	0.98	1.0	0.9	0.27	0.58	0.99
Common Stock Total Equity	0.54	0.44	0.49	0.41	0.55	0.45	-0.33	-0.49	0.43	0.34	0.47	0.58	0.21	0.55		0.17	0.44	0.09	0.9	0.43	0.42	0.54	0.46	0.45	1.0	0.61
Common Stock Shares Outstanding	-0.35	-0.43	-0.46	-0.44	-0.35	-0.41	0.23	0.4	-0.4	-0.62	-0.42	-0.21	-0.66	-0.36	0.17		-0.3	-0.51	0.04	-0.39	-0.42	-0.36	-0.32	-0.01	0.14	-0.29
Non Current Liabilities Total	0.95	0.97	0.95	0.94	0.94	0.97	-0.14	-0.97	0.95	0.85	0.97	0.88	0.77	0.96	0.44	-0.3		-0.14	0.62	0.98	0.97	0.96	0.88	0.06	0.47	0.92
Other Current Assets	0.03	-0.03	0.06	-0.07	0.04	-0.04	-0.52	0.04	-0.02	0.09	-0.04	0.06	-0.11	0.01	0.09	-0.51	-0.14		0.25	-0.1	-0.07	0.03	-0.05	0.51	0.08	0.07
Other Stockholder Equity	0.72	0.61	0.65	0.53	0.73	0.63	-0.46	-0.66	0.63	0.47	0.63	0.78	0.24	0.71	0.9	0.04	0.62	0.25		0.57	0.59	0.71	0.61	0.54	0.9	0.78
Total Liab	0.93	0.96	0.94	0.99	0.91	0.96	-0.06	-0.95	0.91	0.88	0.96	0.82	0.82	0.93	0.43	-0.39	0.98	-0.1	0.57		0.96	0.93	0.86	0.0	0.46	0.88
Property Plant And Equipment Gross	0.97	0.99	0.98	0.93	0.97	1.0	-0.25	-0.98	0.98	0.93	0.99	0.86	0.85	0.98	0.42	-0.42	0.97	-0.07	0.59	0.96		0.98	0.9	0.1	0.46	0.94
Total Current Assets	1.0	0.98	0.99	0.89	1.0	0.99	-0.38	-0.99	0.99	0.9	0.99	0.94	0.78	1.0	0.54	-0.36	0.96	0.03	0.71	0.93	0.98		0.9	0.27	0.57	0.99
Short Term Debt	0.9	0.93	0.88	0.82	0.9	0.9	-0.23	-0.9	0.89	0.83	0.9	0.81	0.74	0.9	0.46	-0.32	0.88	-0.05	0.61	0.86	0.9	0.9		0.14	0.5	0.88
Intangible Assets	0.29	0.12	0.25	-0.04	0.32	0.16	-0.89	-0.16	0.23	0.05	0.16	0.48	-0.04	0.27	0.45	-0.01	0.06	0.51	0.54	0.0	0.1	0.27	0.14		0.45	0.39
Common Stock	0.57	0.48	0.52	0.45	0.58	0.48	-0.33	-0.52	0.46	0.38	0.5	0.6	0.25	0.58	1.0	0.14	0.47	0.08	0.9	0.46	0.46	0.57	0.5	0.45		0.64
Short Term Investments	0.99	0.95	0.97	0.84	0.99	0.96	-0.47	-0.96	0.97	0.85	0.95	0.96	0.72	0.99	0.61	-0.29	0.92	0.07	0.78	0.88	0.94	0.99	0.88	0.39	0.64

Click cells to compare fundamentals

Genmab AS Account Relationship Matchups

Genmab AS fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	15.1B	21.1B	24.6B	30.3B	35.3B	37.1B
Short Long Term Debt Total	181M	319M	425M	597M	770M	808.5M
Other Current Liab	912M	1.1B	1.2B	1.7B	2.3B	2.4B
Total Current Liabilities	938M	1.3B	1.6B	1.8B	2.5B	2.6B
Total Stockholder Equity	14.0B	19.1B	22.2B	27.4B	31.6B	33.2B
Property Plant And Equipment Net	414M	736M	975M	1.3B	1.6B	1.7B
Net Debt	(3.4B)	(6.9B)	(8.5B)	(9.3B)	(14.1B)	(13.4B)
Retained Earnings	2.1B	7.1B	10.0B	15.0B	19.0B	20.0B
Accounts Payable	839M	145M	350M	1.7B	2.3B	2.4B
Cash	3.6B	7.3B	9.0B	9.9B	14.9B	15.6B
Non Current Assets Total	1.2B	2.4B	1.9B	1.9B	2.2B	2.3B
Non Currrent Assets Other	11M	20M	27M	48M	274M	343.6M
Cash And Short Term Investments	11.0B	16.1B	19.3B	22.3B	28.1B	29.5B
Common Stock Total Equity	61.2M	61.5M	65M	66M	75.9M	52.4M
Common Stock Shares Outstanding	63.6M	658.9M	660.5M	660.1M	65.9M	62.6M
Liabilities And Stockholders Equity	15.1B	21.1B	24.6B	30.3B	35.3B	37.1B
Non Current Liabilities Total	158M	769M	863M	1.0B	1.2B	1.3B
Other Current Assets	10.4B	249M	31M	143M	164.5M	156.2M
Other Stockholder Equity	11.8B	11.9B	12.0B	12.2B	12.5B	7.6B
Total Liab	1.1B	2.0B	2.4B	2.8B	3.7B	3.9B
Property Plant And Equipment Gross	414M	736M	1.3B	1.8B	2.3B	2.4B
Total Current Assets	14.0B	18.8B	22.7B	28.4B	33.1B	34.8B
Short Term Debt	26M	42M	62M	74M	90M	94.5M
Intangible Assets	470M	338M	254M	146M	101M	192.7M
Common Stock	61.2M	61.5M	65M	66M	75.9M	55.1M
Short Term Investments	7.4B	8.8B	10.4B	12.4B	13.3B	13.9B
Net Receivables	3.0B	2.5B	3.4B	5.7B	4.9B	5.2B
Inventory	(10.4B)	(249M)	(31M)	(143M)	57M	59.9M
Accumulated Other Comprehensive Income	91.7M	98M	54M	81M	60M	56.5M
Net Tangible Assets	13.6B	18.8B	21.9B	27.3B	31.4B	33.0B
Other Assets	150M	197M	291M	300M	345M	243.7M
Capital Lease Obligations	181M	319M	425M	597M	770M	808.5M
Long Term Investments	149M	1.1B	371M	133M	134M	228.3M
Property Plant Equipment	414M	736M	975M	1.3B	1.5B	1.6B
Net Invested Capital	14.0B	19.1B	22.2B	27.4B	31.6B	20.2B
Net Working Capital	13.0B	17.5B	21.2B	26.6B	30.7B	19.1B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:

How To Invest In Genmab

Details

Is Genmab Stock a good investment?

Details

What is Genmab AS's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.38)

Earnings Share

1.02

Revenue Per Share

30.6997

Quarterly Revenue Growth

0.176

Return On Assets

0.1095

The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Genmab Interest Income vs Ebitda Analysis

Interest Income vs Ebitda

Interest Income vs Ebitda Correlation Analysis

Correlation Coefficient

Interest Income

Ebitda

Genmab AS fundamental ratios Correlations

Genmab AS Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Genmab AS fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Property Plant And Equipment Net
Net Debt	- 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	- 0.98	Net Debt